Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shilpa MedicareNSE:SHILPAMED +2.01%69 5-Year Yield-on-Cost % is 0.08 as of Aug. 04, 2026, which is 60% below its 10-year median of 0.20. GuruFocus rates NSE:SHILPAMED with a GF Score™ of 69/100 and a GF Value™ of ₹389.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 514 Drug Manufacturers companies, Shilpa Medicare ranks worse than 97.28% on this metric.
Shilpa Medicare's yield on cost for the quarter that ended in Mar. 2026 was 0.08.
The historical rank and industry rank for Shilpa Medicare's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:SHILPAMED'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.08 Med: 0.2 Max: 0.78
Current: 0.08
During the past 13 years, Shilpa Medicare's highest Yield on Cost was 0.78. The lowest was 0.08. And the median was 0.20.
NSE:SHILPAMED's 5-Year Yield-on-Cost % is ranked worse than 97.28% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.31
vs NSE:SHILPAMED: 0.08
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Shilpa Medicare 5-Year Yield-on-Cost % Related Terms
NSE:SHILPAMED vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shilpa Medicare 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Shilpa Medicare's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Shilpa Medicare is calculated as
Shilpa Medicare (NSE:SHILPAMED) has a 5-Year Yield-on-Cost % of 0.08 as of Aug. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Shilpa Medicare and its competitors. This is 60% below median its historical median of 0.20. Over the past decade, Shilpa Medicare's 5-Year Yield-on-Cost % has ranged from 0.08 to 0.78. According to the industry distribution chart, Shilpa Medicare ranks #500 out of 514 companies in the Drug Manufacturers industry, placing it in the top 97.3%.
Is Shilpa Medicare's 5-Year Yield-on-Cost % too high?
Shilpa Medicare's current 5-Year Yield-on-Cost % of 0.08 is 60% below median its 10-year median of 0.20. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.78. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.31. Shilpa Medicare's value of 0.08 is 96.5% below this industry median. Based on the distribution chart, Shilpa Medicare ranks #500 out of 514 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shilpa Medicare has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shilpa Medicare ranks #500 out of 514 companies for 5-Year Yield-on-Cost %. This places Shilpa Medicare in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.31. Shilpa Medicare's value of 0.08 is 96.5% below this benchmark. Historically, Shilpa Medicare's own 5-Year Yield-on-Cost % has ranged from 0.08 to 0.78 over the past decade. While the company's 10-year median is 0.20 vs. the industry median of 2.31, Shilpa Medicare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.31, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shilpa Medicare's current 5-Year Yield-on-Cost % of 0.08 is 96.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Shilpa Medicare and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shilpa Medicare's current 5-Year Yield-on-Cost % is 0.08, which is 60% below median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (NSE:SHILPAMED) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹389.27, compared to a current price of ₹623.55 — trading 60.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.08, which is 60% below median its 10-year median of 0.20 and 96.5% below the Drug Manufacturers industry median of 2.31. Shilpa Medicare's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Shilpa Medicare (NSE:SHILPAMED), the current 5-Year Yield-on-Cost % is 0.08 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?
Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued.
The current stock price of ₹623.55 is trading 60.2% above its estimated GF Value™ of ₹389.27.
GuruFocus considers Shilpa Medicare to be Significantly Overvalued.
Key valuation signals for NSE:SHILPAMED:
5-Year Yield-on-Cost %: 0.08 (60% below median its 10-year median of 0.20)
GF Value™: ₹389.27 vs. price of ₹623.55 (60.2% above fair value)
Industry Position: 96.5% below the Drug Manufacturers median (#500 of 514)
No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
69GF Score
Get the complete analysis for NSE:SHILPAMED
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SHILPAMED has been successfully added to your 
